The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Safety data for the PI3Kδ inhibitor umbralisib for lymphoid malignancies
In this interview, Susan O’Brien, MD, of the University of California, Irvine, CA, talks to us about the next-generation PI3Kδ inhibitor umbralisib for patients with relapsed/refractory lymphoid malignancies. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Prof. O’Brien discusses the large-scale safety data presented. She highlights the importance of this data, and compares umbralisib to idelalisib and duvelisib.
